Daiichi Sankyo and Charleston Laboratories Announce Collaboration to Develop and Commercialize Novel, Fixed-Dose Combination Hydrocodone Products for Pain and Opioid-Induced Nausea and Vomiting (OINV) in the US - KNOE 8 News; KNOE-TV; KNOE.com |

Daiichi Sankyo and Charleston Laboratories Announce Collaboration to Develop and Commercialize Novel, Fixed-Dose Combination Hydrocodone Products for Pain and Opioid-Induced Nausea and Vomiting (OINV) in the US

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Daiichi Sankyo, Inc.

Daiichi Sankyo and Charleston Laboratories will collaborate on development and commercialization; Charleston will supply all products and retain an option to co-promote in the United States

TOKYO, PARSIPPANY, N.J. and JUPITER, Fla., Aug. 6, 2014 /PRNewswire/ -- Daiichi Sankyo and Charleston Laboratories, Inc., through its wholly owned subsidiary LOCL Pharma, Inc., announced today that the parties have entered into a strategic collaboration for the development and U.S. commercialization of Charleston Laboratories' novel hydrocodone combination products, including CL-108, being studied for the treatment of moderate to severe acute pain as well as the reduction of Opioid-Induced Nausea and Vomiting (OINV). 

CL-108 combines 12.5 mg of immediate-release promethazine with 7.5 mg of hydrocodone and 325 mg of acetaminophen.  Charleston recently completed a 465-patient phase 3 trial studying the effects of CL-108 as a treatment for moderate to severe acute pain and the reduction of OINV, where CL-108 demonstrated high statistical significance (P<0.01) in both primary endpoints relative to pain reduction and the symptoms of OINV.

Hydrocodone is the most widely prescribed medication in the United States, with more than 131 million prescriptions annually. Opioid-induced nausea affects up to 30 percent of these patients, with approximately 15 percent experiencing vomiting.  These unwanted side effects can result in poor pain control related to difficulties with compliance or return visits to the physician or the hospital for further treatment.  As a consequence, OINV poses a significant burden for patients and prescribers, while contributing significant costs to the healthcare system.

With this collaboration, Daiichi Sankyo, Inc., the U.S. subsidiary of Tokyo-headquartered Daiichi Sankyo Co., Ltd. (TSE: 4568), will be the commercialization partner for CL-108 in the United States. Charleston Laboratories will be responsible for manufacturing activities for CL-108 and will receive the right to co-promote this and other hydrocodone products in the United States.

Under the terms of the agreement, which is pending Hart-Scott-Rodino clearance, Charleston Laboratories will receive $200 million, split evenly between an upfront cash payment and a near-term milestone and up to an additional $450 million in milestone payments connected to the filing and approval of its novel fixed-dose hydrocodone products in the United States.  In addition, Charleston Laboratories will receive an escalating, tiered, double-digit share of the gross operating margin from the products.  

"We are proud to partner with Charleston Labs on this exciting and unique fixed-dose combination tablet, which will seek to simultaneously address severe pain and opioid-related nausea and vomiting to benefit patients," said Dr. Mahmoud Ghazzi, MD, PhD, Global Head of Development and Executive Vice President at Daiichi Sankyo Co., Ltd.

"CL-108 represents an opportunity at the intersection of innovation and patient need," said Ken Keller, President, U.S. Commercial of Daiichi Sankyo, Inc. "Daiichi Sankyo has proven success in the U.S. primary care arena, a key market for pain management, and we look forward to the potential of CL-108."

"From our inception, it has been our goal to identify an industry-leading partner that is patient-focused, with a shared appreciation for the importance of educating healthcare providers on the significant issue of Opioid-Induced Nausea and Vomiting," said Ryan Baker, Founder and Chief Operating Officer of Charleston Laboratories. "Daiichi Sankyo has successfully commercialized several medicines in the United States, and we feel they are the ideal strategic fit for Charleston's lead asset, CL-108."

"Charleston is extremely pleased to enter into this exclusive US license agreement with Daiichi Sankyo," said Paul Bosse, Founder, President and Chief Executive Officer of Charleston Laboratories. "We look forward to applying our strong clinical and regulatory capabilities toward the goal of improving patient well-being.  This agreement highlights Charleston's tenacity and our long-term commitment to build a preeminent pain company that benefits patients and shareholders alike."

Wilson Sonsini Goodrich & Rosati acted as legal counsel to Charleston Laboratories.

About Charleston Laboratories, Inc.
Charleston Laboratories, Inc. is a privately held, specialty pharmaceutical company focused on the research and development of novel pain products to significantly reduce the burdensome side effects related to opioid analgesics and other products.  Charleston's product pipeline currently seeks to address unmet needs in Opioid-Induced Nausea and Vomiting (OINV), Postoperative Nausea and Vomiting (PONV), Chemotherapy-Induced Nausea and Vomiting (CINV), Radiation-Induced Nausea and Vomiting (RINV), and Migraine-Induced Nausea and Vomiting (MINV).  Charleston Laboratories intends to enter into discovery and commercialization alliances with partners motivated to introduce novel pain therapies that reduce the burdensome side effects related to opioid analgesics and other products. For more information, please visit www.charlestonlabs.com.

About Daiichi Sankyo
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, dyslipidemia and bacterial infections used by patients around the world, the Group has also launched treatments for thrombotic disorders and is building new product franchises.  Furthermore, Daiichi Sankyo research and development is focused on bringing forth novel therapies in oncology and cardiovascular-metabolic diseases, including biologics.  The Daiichi Sankyo Group has created a "Hybrid Business Model," to respond to market and customer diversity and optimize growth opportunities across the value chain. For more information, please visit: www.daiichisankyo.com.  Daiichi Sankyo, Inc., headquartered in Parsippany, New Jersey, is a member of the Daiichi Sankyo Group.  For more information on Daiichi Sankyo, Inc., please visit www.dsi.com.

Daiichi Sankyo Logo

 

Charleston Laboratories Logo

Logo - http://photos.prnewswire.com/prnh/20140806/134234  
Logo - http://photos.prnewswire.com/prnh/20140806/134233

©2012 PR Newswire. All Rights Reserved.

  • Most Popular StoriesMost Popular StoriesMore>>

  • Tallulah toddler dies in shooting accident

    Tallulah toddler dies in shooting accident

    Tuesday, September 16 2014 9:19 AM EDT2014-09-16 13:19:53 GMT
    MADISON PARISH, La. (KNOE 8 News) - Tallulah Police confirm a three year-old boy has died in a shooting incident Monday afternoon. Police say the child shot himself after finding a loaded gun in a home in Tallulah.
    MADISON PARISH, La. (KNOE 8 News) - Tallulah Police confirm a three year-old boy has died in a shooting incident Monday afternoon. Police say the child shot himself after finding a loaded gun in a home in Tallulah.
  • Mom held without bail-infants found dead

    Mom held without bail-infants found dead

    Monday, September 15 2014 10:48 AM EDT2014-09-15 14:48:16 GMT
    (CNN)-A foul smell leads police to a Massachusetts home. What they found inside landed a mother behind bars.
    (CNN)-A foul smell leads police to a Massachusetts home. What they found inside landed a mother behind bars.
  • 2014 ArkLaMiss Fair Schedule

    2014 ArkLaMiss Fair Schedule

    Tuesday, September 2 2014 2:37 PM EDT2014-09-02 18:37:25 GMT
    2014 ArkLaMiss Fair Schedule of Events
    2014 ArkLaMiss Fair Schedule of Events
  • Husband goes to work, not seen since

    Husband goes to work, not seen since

    Monday, September 15 2014 6:49 PM EDT2014-09-15 22:49:41 GMT
    NATCHITOCHES, La. (KNOE 8 News NPD) - The Natchitoches Police Department is asking the Public with assistance in locating a missing person.
    NATCHITOCHES, La. (KNOE 8 News NPD) - The Natchitoches Police Department is asking the Public with assistance in locating a missing person.
  • Pastor speaks about his loss as he mourns the death of his daughter

    Pastor speaks about his loss as he mourns the death of his daughter

    Monday, September 15 2014 10:33 PM EDT2014-09-16 02:33:13 GMT
    WEST MONROE, La. (KNOE 8 News) - A West Monroe family continues to mourn the loss of their thirteen-year-old daughter. Sarah Grace Tellifero received a fatal shock of electricity while swimming at Lake Bruin with her church youth group.
    WEST MONROE, La. (KNOE 8 News) - A West Monroe family continues to mourn the loss of their thirteen-year-old daughter. Sarah Grace Tellifero received a fatal shock of electricity while swimming at Lake Bruin with her church youth group.
  • Arklamiss Fair gearing up for a great year

    Arklamiss Fair gearing up for a great year

    Tuesday, September 16 2014 5:11 AM EDT2014-09-16 09:11:13 GMT
    MONROE, La. (KNOE 8 News)- If you drive pass the Monroe Civic Center you may wonder why the whole area is closed in with heavy machinery inside.
    MONROE, La. (KNOE 8 News)- If you drive pass the Monroe Civic Center you may wonder why the whole area is closed in with heavy machinery inside.
  • Boy, 3, dies after finding loaded gun

    Boy, 3, dies after finding loaded gun

    Tuesday, September 16 2014 9:37 AM EDT2014-09-16 13:37:38 GMT
    TALLULAH, La. (AP) - Tallulah Police are investigating the accidental shooting death of a child.
    TALLULAH, La. (AP) - Tallulah Police are investigating the accidental shooting death of a child.
  • Shooting at Monroe Daycare Center

    Shooting at Monroe Daycare Center

    Friday, September 12 2014 2:59 PM EDT2014-09-12 18:59:51 GMT
    Monroe, La (KNOE 8 News & MPD)- The Monroe Police Department responded to a shooting in the parking lot of the Wonderland Daycare Center located at 1705 Hickory Street Friday morning.
    Monroe, La (KNOE 8 News & MPD)- The Monroe Police Department responded to a shooting in the parking lot of the Wonderland Daycare Center located at 1705 Hickory Street Friday morning.
Powered by WorldNow
All content © Copyright 2000 - 2014 WorldNow and KNOE. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.